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In Brief
Antibodies against the TWEAK receptor
Fn14 prevent tumor-induced cachexia
and extend lifespan by inhibiting weight
loss and inflammation, although having
only moderate effects on tumor growth.
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The cytokine TWEAK and its cognate receptor Fn14
are members of the TNF/TNFR superfamily and are
upregulated in tumors. We found that Fn14, when
expressed in tumors, causes cachexia and that anti-
bodies against Fn14 dramatically extended lifespan
by inhibiting tumor-induced weight loss although
having only moderate inhibitory effects on tumor
growth. Anti-Fn14 antibodies prevented tumor-
induced inflammation and loss of fat and muscle
mass. Fn14 signaling in the tumor, rather than host,
is responsible for inducing this cachexia because tu-
mors in Fn14- and TWEAK-deficient hosts developed
cachexia that was comparable to that of wild-type
mice. These results extend the role of Fn14 in wound
repair and muscle development to involvement in
the etiology of cachexia and indicate that Fn14
antibodies may be a promising approach to treat
cachexia, thereby extending lifespan and improving
quality of life for cancer patients.INTRODUCTION
Fn14 (tumor necrosis factor receptor superfamily member 12A;
TNFRSF12A) and its ligand TWEAK (TNFSF12) have been shown
to playmultiple roles in the process of wound repair and can pro-
mote angiogenesis, proliferation, migration, apoptosis, and
inflammation (Burkly et al., 2011; Campbell et al., 2004; Vince
and Silke, 2006; Winkles, 2008). Consistent with such a role, its
expression is strongly induced by growth factors in vivo at sites
of tissue injury and remodeling (Wiley et al., 2001;Winkles, 2008).CFn14 expression is also increased in solid tumors (Culp et al.,
2010; Wiley et al., 2001). Fn14 signaling therefore contributes
to carcinogenesis, and targeting this pathway with monoclonal
antibodies can inhibit tumor growth (Culp et al., 2010; Winkles,
2008).
Cachexia is a complex disease, best described as a metabolic
disorder that includes progressive muscle wasting with or
without the loss of fat stores. It frequently presents in the terminal
stages of many chronic illnesses, including cancer (Tisdale,
2009), and may be present in 50%–80% of patients with solid
tumors (Dewys et al., 1980; Walsh et al., 2000). Although
cachexia reduces patient survival and response to chemo-
therapy andmay account for25%of all cancer deaths (Warren,
1932), the molecular mechanisms are unknown, and there are
no FDA approved drugs to treat it. Attempts to cure cachexia
by increasing appetite or nutrition have proven unsuccessful in
clinical trials. However, it has been suggested that interventions
for cachexia could potentially be developed by targeting inflam-
matory processes that occur in concert with the wasting and
metabolic imbalance that characterize cachexia (Muscaritoli
et al., 2010).
Interleukin-1 (IL-1), IL-6, TNF, and interferon-g are inflamma-
tory cytokines that have been suggested to play a role in
cachexia (Argile´s et al., 2009; Tisdale, 2009). Glucocorticoids
may also contribute to cachexia by upregulating tumor-derived
factors such as lipid-mobilizing factor, which activates degrada-
tive pathways in adipose tissue leading to the breakdown of fat
deposits and disrupted metabolic processes (Islam-Ali and Tis-
dale, 2001; Russell and Tisdale, 2005). Most recently, it has
been shown that activation of the activin type-2 receptor ActRIIb
by transforming growth factor b (TGF-b) family ligands drives a
cachectic phenotype in mice and the degradation of contractile
proteins through the ubiquitin-proteasome pathway. Recombi-
nant decoy ActRIIb inhibited activation of this pathway andell 162, 1365–1378, September 10, 2015 ª2015 Elsevier Inc. 1365
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Figure 1. Fn14 Antibodies Antagonize
TWEAK/Fn14 Signaling
(A) MEF H-Ras V12 cells expressing inducible
hFn14 stained with indicated antibodies. Red:
antibody staining; black: secondary antibody
alone.
(B) Western blot of lysates from H-Ras V12 MEFs
expressing inducible hFn14 ± induction probed
with indicated Fn14 antibodies.
(C) Western blot of HEK293T cells transiently
transfected with the indicated VSV or HA-tagged
TNFSFR probed with indicated antibodies. Arrows
indicate the expressed protein. Note 001 blot (right)
was reprobed with anti-HA.
(D) GFP fluorescence of HEK293T NF-kB GFP re-
porter cells stimulated ± 100 ng/ml of Fc-TWEAK
for 24 hr (pink), and cells co-incubated with the
indicated antibodies (gray).
(E) Kym1 cell-death assay with increasing Fc-
TWEAK dose and co-incubated with indicated
antibodies for 24 hr, harvested, stained with PI, and
percent PI-positive cells assessed determined
from flow cytometry.
Data are means ± SEM (n = 3). See also Figure S1.significantly increased survival and muscle mass of mice
bearing cachexia-inducing tumors (Zhou et al., 2010). Unfortu-
nately, however, decoy ActRIIb in clinical trials resulted in treat-
ment-related bleeding issues in healthy adults and boys with
Duchenne muscular dystrophy and were therefore stopped
and have not been pursued for cachexia treatment.
Because of the demonstrated involvement of Fn14 signaling in
tumor progression, we began our studies with the hypothesis
that an antagonistic monoclonal antibody targeting Fn14 would
inhibit tumor growth (Vince and Silke, 2006; Winkles, 2008). We
developed and characterized three antagonist monoclonal anti-
bodies against Fn14. Two of these antibodies showed variable
ability to block tumor growth but were strikingly effective at
preventing tumor-induced weight loss. We demonstrated that
the tumor-induced loss of lean and fat mass is consistent with
the development of cachexia. In addition, our Fn14 antibodies
were able to prevent and reverse tumor-induced cachexia in
different tumor models. We also demonstrated that the role of
Fn14 in cachexia is independent of both host- and tumor-derived
TWEAK.We further showed that although reported to be upregu-
lated during atrophy, muscle-localized Fn14 is not actively
involved in the loss of muscle mass, supporting the idea of an
alternative role such as repair/regeneration. Our results support
the hypothesis that inhibiting Fn14 signaling has therapeutic po-
tential for cancer-induced cachexia.1366 Cell 162, 1365–1378, September 10, 2015 ª2015 Elsevier Inc.RESULTS
Monoclonal Antibodies against
Fn14
To test the hypothesis that inhibition of
Fn14 would limit tumor growth, we gener-
ated antagonist monoclonal antibodies
against Fn14 by inoculating wild-type
mice with recombinant human Fn14-Fcand generated hybridomas as previously described (Galfre` and
Milstein, 1981). Three monoclonal antibodies, 001, 002, and
004, were positive against a mouse embryonic fibroblast (MEF)
cell line stably expressing inducible human Fn14 (hFn14; Fig-
ure 1A), as was a commercially available control anti-human
Fn14, ITEM1 (Nakayama et al., 2003). ITEM1 and our three anti-
bodies detected hFn14 specifically by western blot (Figure 1B).
Human and mouse Fn14 are 92% identical in the extracellular
domain, and two of the antibodies, 001 and 002, reacted against
the uninduced MEF cell lines that express endogenous murine
Fn14 (Figure 1A).
Because members of the TNF receptor superfamily (TNFRSF)
share homology in their extra-cellular domains, these proteins
are most likely to cross-react with Fn14 antibodies. However,
several are only expressed in specific hematopoietic lineages,
making it difficult to rule out cross-reactivity by screening cell
lines. Therefore, VSV- or HA-tagged TNFRSF members were
overexpressed in HEK293T cells and reacted with either a
VSV, HA, 001, or 002 antibody. All TNFRSF receptors were ex-
pressed and detected by VSV or HA antibodies; however, only
Fn14 was detected by 001 and 002 (Figure 1C).
TWEAK activates both canonical and non-canonical NF-kB
signaling pathways (Salzmann et al., 2013; Varfolomeev et al.,
2007, 2012; Vince et al., 2008). To address whether the Fn14
antibodies activated or blocked Fn14-dependent signaling, we
Figure 2. Ectopic Fn14 Expression in Tu-
mors Causes Loss of Body Weight
(A) Female C57BL/6 mice injected with 5 3 106
tumor cells (day 1). Mean tumor volume ± SEM of
three independent experiments (Fn14, n = 26;
Fn14-GPI, n = 20; H-Ras, n = 6).
(B) Representative images of in situ tumors from
Fn14-expressing tumors (left) or Fn14-GPI-
expressing tumors (right). Bottom image, dis-
aggregated individual tumors from Fn14 (left) and
Fn14-GPI (right).
(C) Fixed tumor sections stained with H&E. Left:
Fn14-expressing tumor, and right: Fn14-GPI-ex-
pressing tumor taken on day 11. Images are 103
(upper, scale bar 160 mm) and 403 magnification
(lower, scale bar 40 mm). Blue box represents area
shown in 403 images.
(D) Body weight from mice in (A) standardized
against starting weight. Data are means ± SEM.used aHEK293T cell line that expresses endogenous hFn14, sta-
bly transducedwith a lentiviral NF-kB reporter vector (Vince et al.,
2008; Figure 1D). The antibodieswere unable to stimulateNF-kB,
demonstrating that, in this assay, they are not Fn14 agonists (left
column, Figure 1D). They did however block TWEAK/hFn14-
induced NF-kB (right column, Figure 1D). To functionally assess
the ability of our antibodies to inhibit TWEAK/hFn14 signaling,
we used Kym1 cells that are sensitive to cell death induced by
TWEAK (Schneider et al., 1999; Vince et al., 2008). We co-incu-
bated Kym1 cells ± TWEAK (at 5, 50, or 200 ng/ml) and mono-
clonal antibodies at a concentration of 1 mg/ml for 24 hr. Adherent
and floating cells were harvested and stained with propidium
iodide (PI), and the percentage of dead, PI-positive cells was
determined by flow cytometry. Antibodies 001 and 002, but not
004, inhibited TWEAK-induced death of Kym1 cells (Figure 1E).
Consistent with results from the other assays, 001 and 002
bound both recombinant human and mouse Fn14 extracellular
domains, whereas ITEM1 bound better to hFn14 than to mouse
(Figure S1A). To define the epitope, we generated two ‘‘sub-
domains’’ of the extracellular domain of Fn14 as peptides (Brown
et al., 2006) and assessed antibody binding by quantitative
ELISA. All antibodies bound efficiently and specifically to sub-
domain 2 but not to sub-domain 1 (Figures S1B and S1C). These
results demonstrate that IgG2b 001 and IgG1 002 antibodies
bind specifically to an extracellular epitope present on both hu-
man and mouse Fn14 receptor.
Fn14-Expressing Tumors Cause Severe Weight Loss
in Mice
To test our hypothesis that an Fn14 antibody could inhibit
tumor growth, we generated an Fn14-expressing tumor cellCell 162, 1365–1378, Sepline and equivalent control cell lines
to generate tumors in wild-type mice.
MEFs derived from C57BL/6 embryos
and transformed with an H-Ras V12
oncogene were infected with an hFn14-
expressing lentivirus. As a control, we
infected the same parental cell line with
a lentivirus expressing only the extracel-lular domain of hFn14 fused to a GPI anchor. Both hFn14 and
control cell lines formed tumors when injected into syngeneic
C57BL/6 mice and initially grew at similar rates (Figure 2A).
Post-mortem analysis of these mice revealed increased vascu-
lature (Figure 2B) and tumor-invasive capacity (Figure 2C) in
the hFn14-expressing tumors when compared with controls.
Surprisingly, 8 days post-inoculation, mice bearing hFn14-ex-
pressing tumors, but not the control tumors, suffered rapid
weight loss, and their overall health deteriorated quickly (Fig-
ure 2D). It was apparent the mice bearing Fn14 tumors were
suffering from cachexia.
Fn14 Antibodies Block Fn14-Induced Cachexia in Mice
We next assessed the effect of anti-Fn14 therapy using the
monoclonal antibody 001 against the weight loss seen in the
mice bearing Fn14-expressing tumors. Mice were inoculated
with MEF tumor cells expressing Fn14 or not and just prior to ex-
pected weight loss (day 6) were treated with 001 or an IgG2b iso-
type control. These hFn14-expressing tumors caused a rapid
loss of body mass, and a single treatment with anti-Fn14, but
not the control antibody, substantially prevented this loss (Fig-
ures 3A and S2A), even though tumor mass and volume were
not significantly different between groups (Figure S2B). Fn14 tu-
mors caused a decrease in mass of the tibialis anterior (TA) and
plantaris muscles and a trend for lower muscle mass of extensor
digitorum longus (EDL), soleus, gastrocnemius, and quadriceps
(Figure 3B). There was no significant change in heart mass in
Fn14 tumor-bearing mice (Figure 3C) but a significant decrease
in subscapular fat mass (Figure 3D). The loss of muscle and fat
mass in hFn14-expressing tumor mice was reduced by a single
injection of anti-human Fn14 antibody (Figures 3B–3D).tember 10, 2015 ª2015 Elsevier Inc. 1367
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Figure 3. Anti-Fn14 Prevents Cachexia Caused by Fn14 Tumors
Female C57BL/6mice inoculated withMEFs transduced with Fn14 (H-Ras V12 Fn14) or the parental MEF line (H-Ras V12) on day 1.Mice were treated with IgG2b
control (H-Ras V12, H-Ras V12 Fn14, n = 8/group) or 001 (H-Ras V12 Fn14+001, n = 8) on day 6.
(A) Group body mass standardized against starting weight ± SEM. Antibody treatment (Y; 5 mg/kg).
(B) Day 11, muscles were excised and weighed. TA: tibialis anterior, EDL: extensor digitorum longus, Gastroc: gastrocnemius, Quad: quadriceps.
(C) Heart and (D) subscapular fat were excised and weighed. Data are means ± SEM (n = 8).
(E) Tetanic force production (expressed relative to initial maximum force) during and after 4 min of fatiguing intermittent stimulation in TAmuscles in situ. Data are
means ± SEM (n = 8).
(F) Frozen TA muscle sections stained with H&E and reacted for anti-laminin (red), anti-myosin IIa (N2.261, green), and SDH activity (blue). Scale bar
represents 100 mm.
(G) Quantitation of IL-6 mRNA in TA muscles.
*p < 0.05 versus MEF v12 Hras; yp < 0.05 versus MEF v12 Hras Fn14. ap < 0.05 main effect MEF v12 Hras versus MEF v12 Hras Fn14, bp < 0.05 main effect MEF
v12 Hras versus MEF v12 Hras Fn14+001, cp < 0.05 main effect MEF v12 Hras Fn14 versus MEF v12 Hras Fn14+001. Data are means ± SEM (n = 8).
See also Figure S2.In addition, the contractile properties of muscles in live mice
wereassessedonday11, but therewerenosignificantdifferences
between groups in grip strength (data not shown), and in anesthe-
tizedmice there were no differences in peak twitch force (data not1368 Cell 162, 1365–1378, September 10, 2015 ª2015 Elsevier Inc.shown), peak tetanic force, and specific (normalized) force of TA
muscles in situ (Figure S2C). However, tetanic force over a range
of stimulation frequencies (10–300 Hz) was lower in TA muscles
from mice with hFn14 tumors than from mice bearing control
Figure 4. Fn14 Antibodies Prevent Tumor-
Induced Weight Loss
(A) Flow cytometric analysis of mouse tumor cell
lines LLC and C-26 adapted to low serum (0.5%
FCS) and stained with anti-Fn14 (ITEM1). Black
trace: unstained cells, orange trace: secondary
stain only, red trace: anti-Fn14.
(B) Average tumor volume for CD2F1 male mice
inoculated with 1 3 106 cells (s.c., day 1). Data are
means ± SEM. Antibody treatment (Y); 10 mg/kg.
*p < 0.05 versus C-26.
(C) A Kaplan-Meier survival curve. p < 0.01 log-
rank (Mantel-Cox) test.
(D) Group average mouse weight standardized
to starting weight ± SEM. *p < 0.05 control versus
C-26; yp < 0.05 control versus C-26+002; p^ < 0.05
pair-fed versus C-26; zp < 0.05 C-26 versus
C-26+002.
Drop in average tumor volume of treated animals
at day 21 in (B) coincides with culling of two
mice due to ethical considerations (also noted by[
in C and D).tumors, and this reduction in force was prevented by treatment
with anti-Fn14 (Figure S2C, top panel). Anti-Fn14 also increased
relative force production during and after a 4 min intermittent
fatiguing stimulation protocol, indicating reduced muscle fatiga-
bility following anti-human Fn14 treatment (Figure 3E).
TA muscle sections were stained with hematoxylin and eosin
(H&E), anti-laminin, and anti-myosin IIa to examine the effect of
Fn14 tumor expression on muscle fiber architecture and cross-
sectional area (Figure 3F). Tumors expressing hFn14 caused
decreasedmuscle fiber cross-sectional area (Figure S2D), which
was due to decreases in size of both type IIa and type IIx/b fibers
(Figure S2E). A single injection of anti-Fn14 prevented the
decrease in muscle fiber size (Figures 3F and S2D). Despite im-
provements in muscle fatigability, anti-Fn14 did not cause a shift
in fiber-type proportions (Figures 3F and S2E) or muscle fiber
oxidative capacity as assessed by succinate dehydrogenase
(SDH) reaction intensity (Figures 3F and S2E). Assessment of
mRNA levels of IL-6, an inflammatory marker of cachexia in TA
muscle, also revealed that hFn14 tumors caused a significant in-
crease in IL-6 expression in TA muscles compared to control tu-
mors, and anti-Fn14 treatment blocked this increase (Figure 3G).
Fn14 Antibodies Increase Survival of Colon-26
Tumor-Bearing Mice
Given that tumor-expressed Fn14 had not been previously re-
ported as a mediator of cachexia, it was important to assess
whether this finding was more widely applicable. We therefore
chose well-published mouse models of cachexia to further vali-
date our findings. We assessed the level of Fn14 expression on
two such tumor cell lines, Lewis lung carcinoma (LLC) and colon-
26 (C-26), and demonstrated that they express low and high
Fn14 levels, respectively (Figure 4A).Cell 162, 1365–1378, SepWe chose to establish and utilize the
C-26 tumor model to test the efficacy
of anti-Fn14 given that the cell line ex-
pressed high levels of Fn14, and thismodel generally displays more marked cachexia. Groups of
five immunocompetent CD2F1 mice were inoculated with C-26
tumor cells, then treated or not with antibody 002 on days 5,
12, 15, and 20 post-inoculation. We chose monoclonal antibody
002 for this model given that it reacted slightly stronger than
001 to mouse Fn14 (Figure 1A). Antibody 002 is a different
isotype than 001 and also has a subtly different Fn14 binding
profile and ability to block Fn14 signaling compared to antibody
001. The tumors grew well, and although they displayed some
inter-individual heterogeneity, growth was slightly slower in the
treated compared to the untreated mice (Figure 4B). The survival
of the treated mice was also extended dramatically (Figure 4C),
and although the tumors in untreated and treated animals were
comparable in size over the 18 days post-inoculation, untreated
mice lost weight rapidly from day 11 onward, whereas treated
mice maintained weight and condition during this period (Fig-
ure 4D). Maintenance of weight in a pair-fed control group
showed that the loss in body mass in the untreated C-26 tumor
mice was not due to differences in food intake (Figure 4D).
Fn14 Antibodies Block C-26 Tumor-Induced Cachexia
To more extensively characterize the weight loss and effect of
anti-Fn14 treatment on C-26 tumor-bearing mice, we treated
10 mice with either anti-Fn14 002 or an isotype control IgG
dosed on days 8, 12, and 16 post tumor inoculation and sacri-
ficed them at day 22. The experiments presented in Figures 5
and 6 were performed in different labs with different sources
of C-26 tumor cell lines than those presented in Figure 4, and
as observed before, untreated C-26 tumor mice began to
lose weight around 11 days post tumor inoculation. Although
there was a slightly slower decline in weight using this alterna-
tive source of C-26 cells, anti-Fn14-treated mice again retainedtember 10, 2015 ª2015 Elsevier Inc. 1369
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Figure 5. Fn14 Inhibition Attenuates Muscle Wasting and Weakness in C-26 Tumor-Bearing Mice
(A) Group average body weight standardized to starting weight ± SEM of CD2F1mice inoculated with PBS or 0.53 106 C-26 cells s.c. (day 1). Antibody injections
(Y; 10 mg/kg). Relative body mass of C-26 from experiment 1 (gray, n = 23) significantly lower than PBS (blue, n = 14) from day 14 (p < 0.05). Body mass of C-26
from experiment 2 (white, n = 10) significantly lower than pair-fed 002-treated C-26 (red, n = 10) from day 16 (p < 0.05). Pair-fed IgG-treated C-26 (black, n = 10)
body mass significantly lower than 002-treated C-26 from day 13 (p < 0.05).
(B) Day 22, tumors excised and weighed, and percent change in tumor-free body mass compared to pre-inoculation weight calculated. Data represent means ±
SEM. *p < 0.05 versus PBS; yp < 0.05 versus C-26 from experiment 2; zp < 0.05 versus pair-fed IgG-treated C-26.
(legend continued on next page)
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body weight (Figure 5A, Exp 1). We also assessed untreated
C-26 tumor-bearing mice and a non-tumor group that were
injected with PBS in place of C-26 cells and pair-fed against
the C-26 group (blue and gray lines, respectively), and the
data indicate reproducibility and that weight loss is unlikely
due to food intake (Exp 2). Tumors in antibody-treated mice
grew slower than in control mice, but weight loss was well
advanced by day 17 when tumor size differences were negli-
gible, indicating that the anti-tumor effect of the antibody
was not the reason for the reduction in cachexia (Figures 5A
and S3A). The preservation of weight in the anti-Fn14-treated
mice was more apparent when the weights of the mice without
tumors were measured (Figure 5B). Furthermore, the mass of
several muscles in anti-Fn14-treated mice was significantly
spared compared to control IgG-treated mice (Figures 5C
and 5D). Heart and fat mass were also spared in anti-Fn14-
treated mice (Figures 5D and 5E). Consistent with the preserva-
tion of muscle mass, peak grip strength in living mice at day 21
was increased in anti-Fn14-treated mice compared to control
IgG-treated mice (Figure 5F). Peak twitch force (Figure 5G),
peak tetanic force (Figure 5H), and tetanic force over a range
of stimulation frequencies (Figure 5I) of TA muscles assessed
in situ were also higher in anti-Fn14-treated animals compared
to control-treated mice. After determining peak tetanic force,
muscles were subjected to a 4 min intermittent stimulation
protocol to induce muscle fatigue. Again, TA muscles of anti-
Fn14-treated mice produced higher forces throughout most
of the fatiguing stimulation protocol than control treated mice
(Figure 5J).
These results demonstrated that the cachexia seen in C-26
tumor-bearing mice was caused by Fn14 and that those
mice treated with anti-Fn14 antibody were not succumbing to
cachexia. To investigate this at the cellular level, TA muscle
sections were stained with H&E, revealing a larger fiber size in
anti-Fn14-treated mice compared with the control treated mice
(Figure 6A). Sections stained with anti-laminin confirmed the
preservation of fiber size in anti-Fn14-treated mice (Figures 6B
and S3B), and co-staining with a myosin IIa-specific antibody
(N2.261) to identify type IIa and type IIx/b fibers revealed that
the cross-sectional area of both fast, oxidative type IIa fibers
and fast, glycolytic type IIx/b fibers was increased by anti-
Fn14 treatment (Figures 6C and 6D). The proportion of type IIa
and type IIx/b fibers was similar between treated and untreated(C–E) Day 22, selected tissues were excised and weighed. (C) EDL: extensor digi
Quad: quadriceps. (E) Epididymal fat. Data are means ± SEM. *p < 0.05 versus P
(F) Day 21, whole-body strength was assessed using a grip-strength meter. D
experiment 2; zp < 0.05 versus pair-fed IgG-treated C-26.
(G and H) Day 22, (G) peak twitch force and (H) peak tetanic force of TA muscle w
versus C-26 from experiment 2; zp < 0.05 versus pair-fed IgG-treated C-26.
(I) Day 22, tetanic force production at stimulation frequencies of 10–350 Hz ass
experiment 1 (gray, n = 9) significantly lower than PBS (blue, n = 7) from 30 Hz (
pair-fed 002-treated C-26 (red, n = 10) from 75 Hz (p < 0.05). Force from pair-fed
100–200 Hz (p < 0.05).
(J) Tetanic force production during and following 4 min fatiguing intermittent stim
C-26 from experiment 1 (gray, n = 8) compared to PBS (blue, n = 7, p < 0.001 grou
IgG-treated C-26 (black, n = 9) compared to pair-fed 002-treated C-26 (red, n =
Exp 1 and Exp 2: experiments 1 and 2, respectively. In graphs in (B)–(F), double f
Figure S3.
Cgroups (Figure 6D), as wasmuscle fiber oxidative capacity as as-
sessed by SDH (Figures 6C and S3C). These results show that
protection ofmusclemass and strength with anti-Fn14 treatment
was due to the protection of individual muscle fibers and not a
shift in muscle fiber-type composition.
Muscle atrophy has been shown to occur through activation
of the ubiquitin proteasome and inhibition of the Akt/p70S6K
pathway inmuscle (Dogra et al., 2007).We therefore investigated
the effect of anti-Fn14 treatment on the mRNA expression of the
ubiquitin ligases MuRF-1 and atrogin-1 in the TA of these
cachectic mice. Consistent with the increase in muscle mass
and fiber size in anti-Fn14-treated mice, MuRF-1 and atrogin-1
mRNA expression was reduced in the TA muscles of anti-
Fn14-treated tumor-bearing mice compared with untreated
and IgG-treated mice (Figure 6E). In addition to loss of muscle,
mRNA expression of the inflammatory cytokines IL-6 and TNF
were significantly higher in TA muscles from C-26 control and
control IgG-treated mice compared to anti-Fn14-treated mice,
indicating that anti-Fn14 protects mice from muscle loss and
also reduces the cachectic inflammatory phenotype (Figure 6F).
Not All Fn14 Antibodies Are Anti-cachectic
Given the complete blockade of cachexia onset and progression
with the two antibodies we had tested, we next investigated
whether any Fn14 antibody would be efficacious against the
symptoms of cachexia. We assessed a third antagonistic anti-
body, 004, along with a commercially available antibody that
has been reported to be a weak agonist, ITEM1. 004 is specific
to human Fn14 and unlike either 001 or 002 did not cross-react
with murine Fn14. Given that the MEF Fn14 tumor model ex-
pressed human Fn14, this was an ideal model to test for efficacy
of this antibody. ITEM1, unlike 001, 002, or 004, did not antago-
nize or agonize TWEAK/Fn14 signaling in the NF-kB reporter
assay (Figures 1D and S4A). Human Fn14-expressing MEF tu-
mors were established in mice, and a single dose of antibody
was administered at day 7, just prior to noticeable weight loss
(Figures S4B–S4D), or day 8, the first day of weight loss (Figures
S4E and S4F), to randomized groups of mice. Consistent with
the preceding experiments, 001 and 002 prevented weight loss
induced by Fn14 tumors (Figures S4B, S4D, and S4E) and
improved survival (Figures S4C and S4F). However, 004 and
ITEM1 were unable to prevent Fn14 tumor-induced weight loss
or improve survival. These results suggest that neither the abilitytorum longus, Plant: plantaris. (D) TA: tibialis anterior, Gastroc: gastrocnemius,
BS; yp < 0.05 versus C-26; zp < 0.05 versus pair-fed IgG-treated C-26.
ata are means ± SEM. *p < 0.05 versus PBS; yp < 0.05 versus C-26 from
ere assessed in situ. Data are means ± SEM. *p < 0.05 versus PBS; yp < 0.05
essed in TA muscles in situ. Data are means ± SEM. Force from C-26 from
p < 0.05). Force from C-26 experiment 2 (white, n = 9) significantly lower than
IgG-treated C-26 (black, n = 9) significantly lower than 002-treated C-26 from
ulation assessed in TA muscles in situ. Data are means ± SEM. Force lower in
pmain effect). Force lower in C-26 from experiment 2 (white, n = 8) and pair-fed
10, p < 0.001 group main effect).
orward slash (//) denotes data obtained in two separate experiments. See also
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Figure 6. Fn14 Inhibition Induces Muscle
Fiber Hypertrophy
CD2F1 mice were inoculated with 0.5 3 106 C-26
cells s.c. (day 1) and treated with indicated anti-
body (10 mg/kg; days 8, 12, and 16).
(A) Day 22, TA muscles excised and frozen for
histological analysis. Representative images of
muscle cross-sections stained with H&E and
higher magnification inset are shown. Scale bar
represents 100 mm.
(B) Muscle sections stained with anti-laminin (scale
bar represents 100 mm). See also Figure S3B for
quantification of muscle fiber cross-sectional area
(CSA).
(C) Representative images of muscle sections
and reacted for anti-laminin (red), anti-myosin IIa
(N2.261, green, type IIa fibers), and SDH (blue, fi-
ber oxidative capacity). Scale bar represents
100 mm.
(D) Laminin and N2.261 staining from (C) was used
to quantify CSA (top) and relative proportion (bot-
tom) of type IIa and type IIx/b fibers. Data are
means ± SEM. *p < 0.05 versus C-26; yp < 0.05
versus pair-fed IgG-treated C-26 (n = 8).
(E) MuRF-1 and atrogin-1 mRNA in TA muscles
were quantitated. *p < 0.05 versus untreated PBS;
yp < 0.05 versus untreated C-26 from experiment
2; zp < 0.05 versus pair-fed IgG-treated C-26 (n =
8–9). Data are means ± SEM.
(F) Fn14 inhibition reduced expression of the pro-
inflammatory cytokines IL-6 and TNF, and mRNA
in TA muscles was quantitated. Mean ± SEM. *p <
0.05 versus PBS; yp < 0.05 versus C-26; zp < 0.05
versus pair-fed IgG-treated C-26 (n = 8–9).
Double forward slash (//) denotes data obtained in
two separate experiments. See also Figure S3.to bind human Fn14 nor antagonistic properties of an antibody to
human Fn14 are sufficient to predict its ability to inhibit cachexia.
Host TWEAK and Fn14 Do Not Cause Cachexia
TWEAK/Fn14 signaling directly in muscle tissue has been re-
ported to play a role not only in muscle development but also
inmuscle atrophy (Tajrishi et al., 2014). It was therefore important
to determine whether Fn14 or TWEAK from the host tissue could
be promoting the Fn14-dependent muscle loss seen in our MEF
Fn14 cachexia model. In separate experiments, we established
Fn14 tumors in Fn14/ or Tweak/ mice and compared these
to tumors in wild-type mice. Mice were inoculated with Fn14 or
Fn14-GPI tumor cells on day 1, and body weight and tumor1372 Cell 162, 1365–1378, September 10, 2015 ª2015 Elsevier Inc.size were monitored (Figure 7). Body, tu-
mor, muscle, and epididymal fat weight
were assessed (Figures 7A–7C and S5),
and there were no differences in the
onset, severity, or timing of cachexia in
either strain of knockout mice, suggesting
that the signal for cachexia does not orig-
inate in host tissues but in the Fn14-ex-
pressing tumor cells.
Although these experiments were able
to demonstrate that host TWEAK wasnot a player in cachexia, it was crucial to determine whether
the tumor itself was a source of TWEAK involved in cachexia
onset. We used the monoclonal TWEAK antibody MTW-1 for
this purpose as it has been shown to effectively block the action
of TWEAK inmice at reducing collagen-induced arthritis (Kamata
et al., 2006). We confirmed in vitro that MTW-1, but not an iso-
type control antibody (Rat IgG1), blocked TWEAK-induced NF-
kB (Figure 7D). Wild-type mice bearing MEF Fn14 tumors were
treated withMTW-1 or isotype control on day 7, and body weight
was monitored over time. In contrast to the anti-Fn14 antibody
treatment, MTW-1 (anti-TWEAK) had no effect on the rapid in-
duction of cachexia by the Fn14 tumor (Figure 7E). Together,
these results suggest that neither tumoral nor humoral sources
of TWEAKdrive cachexia in thismodel and that the Fn14/TWEAK
signaling pathway in muscle is not responsible for muscle
atrophy.
Further Assessment of the Role of Muscle Fn14 in
Atrophy
Given that the TWEAK/Fn14 pathway in muscle has been previ-
ously implicated in the induction of muscle atrophy pathways,
yet our studies in knockout mice suggested no involvement,
we next used a specific model whereby atrophy is induced in
muscle by the expression of activin A, a soluble molecule well
known for its involvement in binding the ActRIIb receptor on
muscle cells and activating muscle atrophy pathways. We chose
this model because recently, using next-gen sequencing, we
found that muscle wasting induced by local transduction of
mouse limb muscles with a recombinant adeno-associated
virus-based vector expressing activin A (AAV:ActA) was associ-
ated with upregulation of Fn14 transcription. Abundance of
Fn14 protein was increased approximately 10-fold in muscles
administered the activin-expressing vector, compared with
contralateral limb controls (Chen et al., 2014). Because local
overexpression of activin A was proven to induce Fn14 expres-
sion in this muscle atrophy model, we asked whether induction
of Fn14 was responsible for causing muscle wasting in activin
A-overexpressing muscle or as a downstream consequence of
atrophy pathway activation. To test this, we transduced the right
TA muscle of C57BL/6 mice with an AAV vector expressing acti-
vin A and a control AAV vector in the left muscle. Mice were
treated with Fn14 antibodies 001 or 002 or an IgG control anti-
body 4 days after administration of AAV vectors, for a total of
six injections prior to assessment at the experimental endpoint
4 weeks later. Increased local expression of activin A caused
muscle wasting as expected (Figures 7F and 7G); however,
neither 001 nor 002 blocked activin A-induced muscle loss, indi-
cating that although Fn14 is upregulated in muscle during activin
A-induced muscle wasting, it does not cause loss of muscle
mass.
Translation to Human Cancer
Given the dramatic pro-cachectic effects of Fn14-expressing tu-
mors in mice, we were interested to see whether there were data
that might indicate whether the same scenario pertains to human
cancers. We examined the mRNA expression for a range of can-
cers in the GDAC (Genome Data Analysis Centre) Firehose at the
Broad Institute. As with most databases, the presence of weight
loss is unfortunately not annotated. However, for cancers where
sufficient sample sizes exist, wewere able to demonstrate a pos-
itive correlation for the expression of Fn14with pro-inflammatory
cytokines in human cancers (Figures S6 and S7). In breast, head
and neck, lung, colorectal, and stomach cancer, IL-1a, IL-1b,
IL-6, IL-8, and TNF (Figures S6 and S7) all correlate positively
with Fn14 expression.
DISCUSSION
We developed antibodies to specifically block Fn14 signaling in
order to test the hypothesis that they would reduce tumor growth
and development. Our antibodies were specific and selectedCon the basis that they inhibited TWEAK/Fn14-induced NF-kB
signaling and cell death. We initiated studies in vivo on the basis
that these antagonistic antibodies might impede tumor growth.
Our antibodies, however, have incomplete and tumor-specific
effects on tumor growth.
When we expressed Fn14 on tumors (MEF Fn14 model), it
surprisingly induced severe weight loss and overall decline in
health. Tumors can cause anorexia or suppress appetite (Maccio`
et al., 2012), but loss of weight in these mice was not due to a
tumor effect on feeding because pair-fed controls retained
body mass. Cachexia occurs in the presence of other illness,
and cancer is one such example. The defining hallmark of
cachexia is loss of lean muscle mass and, in some cases, loss
of fat. The poor understanding of the signaling pathways that
cause cachexia has meant that current cachexia therapies
generally target the disease symptoms rather than the cause.
For example, ghrelin, a peptide hormone originally isolated
from the stomach that stimulates appetite, has been used in
cachectic patients to combat loss of body mass (Maccio` et al.,
2012). However, this is ultimately ineffective because it does
not address the cause of the disease.
We therefore investigated the possibility that signaling via
Fn14might contribute to cachexia. In our experiments, untreated
and control-treated tumor-bearing mice lost significant muscle
mass from all of the major skeletal muscles, and this loss was
prevented by treatment with anti-Fn14. Furthermore, muscle
function, along with fat stores, were also retained in the anti-
body-treated mice, and a decrease in inflammatory markers
within target tissues was also observed. We were then able to
extend these findings by reproducing the anti-cachectic ability
of our Fn14-antibodies in the widely studied C-26 mouse model
of cancer cachexia. Thus, targeting Fn14 on tumors presents a
promising means for treatment of cancer cachexia. The finding
that Fn14 is not only involved in wound healing (Winkles, 2008)
but also causative of cancer cachexia is consistent with the
concept that tumors resemble wounds that do not heal (Dvorak,
1986).
We had specifically chosen antibodies to Fn14 that could
antagonize the action of TWEAK, in line with the hypothesis
that Fn14-dependent cachexia is caused by an activation of
signaling through Fn14. Although in vitro our antibodies can
function as antagonists, we cannot rule out that in vivo these
anti-cachectic antibodies are operating via Fc-dependent
multi-merization pathways. In vitro studies showed the potential
of cross-linked Fc domains to reveal agonistic activity (data not
shown). This is a common and often desirable feature of anti-
bodies and has been demonstrated for other Fn14 antibodies
(Culp et al., 2010; Salzmann et al., 2013).
Combined with the ability of our Fn14 antibody to inhibit
cachexia, these observations naturally led to the idea that
TWEAK could be the factor that drives muscle wasting in these
cancer-induced cachexia models, given that it is the only ligand
reported for Fn14 to date. However, the MEF tumors induced
cachexia to the same degree in both Fn14/ and Tweak/
mice, which is inconsistent with this hypothesis. Additionally,
our data also demonstrated that TWEAK blockade (using a
blocking TWEAK antibody) had no effect on the Fn14-induced
cachexia, which raises the question of how Fn14 is inducingell 162, 1365–1378, September 10, 2015 ª2015 Elsevier Inc. 1373
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Figure 7. Host Fn14 and TWEAK Are Not Involved in Cachexia
Wild-type, Fn14/ or Tweak/ mice were injected with MEF H-Ras V12 Fn14 or Fn14-GPI tumor cells (day 1).
(A) Starting and final weight and final body weight minus tumor mass, standardized to starting weight. Exp 1 and Exp 2: experiments 1 and 2, respectively. See
also Figure S5.
(B andC)Groupaverage (B) epididymal fat and (C)muscle (TA, quadriceps, and heart) standardized against startingbodyweight. In graphs, double forward slash (//)
denotes data obtained in two separate experiments. *p < 0.05 versus non-tumor for that strain; yp < 0.05 versus Fn14 tumor for that strain. Data are means ± SEM.
(legend continued on next page)
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cachexia in a ligand-independent fashion. Ligand-independent
receptormulti-merization has been suggested for Fn14 by others
as a possibility for pathway activation; however, this idea has
stemmed from in vitro overexpression data (Brown et al., 2003;
Han et al., 2003), and no in vivo physiological evidence exists
to support this hypothesis. Although speculative, another possi-
bility is the presence of a second unidentified ligand for Fn14.
Although the mechanism remains unclear, there is no doubt
that tumor-localized Fn14 induces cachexia in the models pre-
sented here, and antibody therapy ablates this condition.
In addition to its effects during tumorigenesis, Fn14 signaling
(via the action of TWEAK) has been linked to inhibiting differ-
entiation of myoblast to muscle (Dogra et al., 2006; Girgenrath
et al., 2006) and promoting myoblast proliferation in the pres-
ence of TWEAK. In vivo studies using Fn14 or TWEAK knockout
and TWEAK transgenic mice support the idea that regulating
myogenesis and muscle repair are physiological functions of
the TWEAK/Fn14 signaling axis (Tajrishi et al., 2014; Girgen-
rath et al., 2006; Mittal et al., 2010a, 2010b). Our data from
both Fn14/ or Tweak/ mice, as well as a blocking TWEAK
antibody, demonstrated that, at least in the models presented
here, neither TWEAK nor Fn14 in muscle cells are involved
in inducing muscle atrophy pathways directly. This raises the
question of why Fn14 expression is increased in muscle during
atrophy, and we speculate that this could be in a regenerative
capacity. Supportive of such a hypothesis, Fn14 is required for
the self-renewal of muscle progenitor cells, and Fn14 knockout
mice display delayed muscle regeneration following injury
(Girgenrath et al., 2006). In addition to our data generated from
cancer-cachexia models, the model for activin A overexpression
in muscle promotes upregulation of muscle Fn14 during muscle
wasting. Fn14 antibody treatment did not prevent activin
A-induced muscle loss, and in fact antibody treatment led to
marginally smaller muscle mass than that in control-treated
mice, again supporting the hypothesis of Fn14 functioning in a
regenerative capacity.
Given that our data argues against the possibility that tumor-
derived TWEAK is the causative factor in cancer cachexia and
also against muscle atrophy being induced by signaling via
localization of Fn14 in the muscle itself, this raises the question
of the nature of the soluble factor produced by the tumor that re-
lays the signal to distal tissues. Potential candidates for such
signaling molecules could be activins or myostatin because
cachexia induced by C-26 tumors was prevented by a decoy ac-
tivin receptor (ActRIIb) that inhibits activin/myostatin signaling.
Interestingly, although muscle wasting caused by C-26 tumors
was successfully prevented by the ActRIIb decoy receptor, fat
loss, another feature of cachexia, was unaffected (Zhou et al.,
2010). In contrast, we have shown that anti-Fn14 treatment of
C-26 cachectic animals prevented tumor-induced inflamma-(D) Flow cytometric analysis of HEK293T NF-kBGFP reporter assay. MTW-1 (anti-
and blue underlay).
(E) Standardized group body weight of C57BL/6 mice injected with MEF H-Ras V
IgG, or 002; day 7; 10 mg/kg; Y). Data are means ± SEM (n = 8).
(F) Absolutemass values for TAmuscles injectedwith activin-expressing AAV vect
IgG control.
(G) Percentage change in TA muscle mass, injected with activin-expressing AAV
Ction, fat loss, and reduction in muscle mass and function. Mini-
mally we can conclude that if activin functions downstream of
tumor Fn14 to induce cachexia, it is only one of the compo-
nents produced by Fn14 tumors. Fn14 is therefore an attractive
therapeutic target because it is not required for normal devel-
opment and is generally absent in normal tissue yet increased
in tumors.
Our data implicated tumor Fn14 as an inducer of cachexia
in mice models, and therefore translation of these findings to
humans was crucial. Cachectic mice lose weight very rapidly,
whereas in human cancer patients, cachexia usually progresses
slowly, with an average loss of 5%bodymass over 12months. In
murine tumor models, the tumor can account for as much as
10% of the total mouse weight; in humans, tumor mass as a
proportion of body weight rarely exceeds 1%. Mice also have
a different metabolism than humans. Despite the need to be
cautious when translating results from mouse models to hu-
mans, it is noteworthy that in our experiments similarily sized
tumors caused very different cachectic effects. This demon-
strates that cachexia is an active, independent process with
the tumor directly driving the loss of muscle and fat.
Cancer cachexia has been estimated to be as high as 80% of
all cancer cases (Wallengren et al., 2013), and cachexia has been
attributed to a patient’s inability to tolerate intensive treatment
regimens (Argile´s et al., 2009; Murphy and Lynch, 2009). Unfor-
tunately, current databases are remarkably deficient concerning
the presence of cachexia or its contribution to patient well-being
and survival. Even so, our TCGA database analysis promisingly
revealed positive correlations between many inflammatory cyto-
kines implicated in cancer cachexia and Fn14 transcripts in pa-
tients. The typical lack of diagnosis of cachexia in patient cohorts
means, however, that the data cannot directly address whether
Fn14 expression plays a role in cachexia.
A therapy that directly targets cancer-associated cachexia
is desperately needed. We have demonstrated that anti-Fn14
reagents present a tangible treatment and must now be tested
for their efficacy in cancer patients presenting with hallmarks
of cachexia. Prior to this, however, there is a pressing and urgent
need to generate patient sample data that acknowledge and re-
cord central components to cachexia.EXPERIMENTAL PROCEDURES
Monoclonal Antibody Generation—Immunization of Mice,
Hybridoma Production, and Purification
Recombinant Fn14-Fc (Amgen) was used for immunizations. Female Balb/c
mice were immunized intraperitoneally (i.p.) with 15 mg of antigen emulsified
in Complete Freund ’s adjuvant (Sigma). Incomplete Freund’s adjuvant was
used for subsequent boosts performed at 4 week intervals and final i.p. injec-
tion 3 days before spleen removal.TWEAK), Rat IgG control, or antibody 002 (red) ± 0–200 ng/ml Fc-TWEAK (gray
12 Fn14 tumor cells (day 1) and antibody treated (anti-TWEAK MTW-1, control
ors (right TA, RTA) or control vector (left TA, LTA); mice treatedwith 001, 002, or
vectors, compared with contralateral muscles receiving control vector.
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Hybridoma fusions with SP20 cells were performed using ClonaCell-HY
Hybridoma Kit (StemCell Technologies, Inc.). Selection and cloning steps
were performed on methylcellulose-based semi-solid media in 96-well plates.
Antibody accumulated from hybridomas grown in serum-free conditioned
medium and purified with Protein A Sepharose HiTrap MabSelect Xtra (GE
Healthcare). Neutralized eluate from Protein A was concentrated and buffer
exchanged with PBS using a vivaspin 20 column (Sartorius). All antibodies
had endotoxin < 0.05 EU/mg, determined using Charles River Endosafe PTS.
Antibody Isotyping and Antibodies
Antibodies were isotyped using the BD Cytometric Bead Array. ITEM1, IgG2b,
IgG1, and TWEAK (MTW-1); rat IgG1 (Biolegend); anti-VSV (Sigma); anti-HA
(made in-house); and AlexaFluor-647 secondary (Invitrogen) were used.
Generation of Constructs and Cell Lines
The 4-hydroxytamoxifen (4-OHT) inducible lentiviral vector previously
described (Vince et al., 2007) was used to express human Fn14, or the Fn14
extracellular region fused to the TrailR3 GPI (Bossen et al., 2006), to create
Fn14-GPI. Wild-type C57BL/6 MEFs were immortalized with a lentiviral SV40
Large T construct and transformed with a retroviral H-Ras V12 construct.
This cell line was then transduced for expression of GEV16 and either Fn14
or Fn14-GPI. One hundred nanomolar 4-OHT was used for protein induction.
Transfections and Western Blotting
HEK293T cells were transiently transfected with DNA encoding TNFRSF
members (Bossen et al., 2006) using Lipofectamine 2000. At 24 hr, cells
were harvested and lysed in RIPA buffer. Inducible cell lines were grown to
50% confluency, and Fn14 expression induced for 48 hr. Cells were har-
vested, washed, and resuspended in 20 mM Tris, pH 7.4, 10 mg/ml DNase1
andRNaseA. Genomic DNA from lysed cells was sheared (27G insulin syringe),
samples centrifuged, supernatant collected, and further centrifuged. The
pellet was resuspended in 1M Tris, 0.4% SDS, and proteins were separated
by reducing SDS-PAGE and western blotted. HRP-conjugated secondary
goat anti-mouse was used for detection.
Flow Cytometry
Cells (1 3 105) were incubated with antibody, washed, and stained with
AlexaFluor-647-conjugated goat anti-mouse IgG, and flow cytometry was
performed with a BD FACSCanto II. Data analysis was done with FlowJo.
Fn14 expression was induced 24 hr prior.
HEK293T NF-kB GFP Assay
HEK293T cells containing a stably integrated lentiviral vector and an NF-kB
promoter driving GFP (pTRH1 System Biosciences) were incubated for
24 hr ± Fc-TWEAK (5, 50, 100, or 200 ng/ml), ± antibodies. GFP fluorescence
was measured by flow cytometry.
Kym1 Cell-Death Assay
Kym1 cell-death assays were performed as described (Vince et al., 2008).
Briefly, 24 hr after TWEAK stimulation, live and dead cells were harvested,
stained with PI, and analyzed by flow cytometry.
Tumor Cell Lines and Tumor Studies
Two independent sources of C-26 cells from Cell Line Services (Germany)
(Figure 4) and a gift from Martha Belury (Ohio State University, Columbus,
OH, USA) (Figures 5 and 6) were used; LLC were sourced from European
Collection of Cell Cultures. Cells were cultured in 10% DMEM (MEF and
LLC) or 10% RPMI (C-26). Mice were obtained from Animal Resources Centre
(Canning Vale, Western Australia) or Monash Animal Services (Victoria), and all
experiments were approved by the relevant Animal Ethics Committees from La
Trobe University (AEC 13-52, 10-54, 11-37, and 10-19B), University of Mel-
bourne (AEC 1112069), or the AlfredMedical Research and Education Precinct
(AEC E/1289/2012/B). Tumor measurements were taken using digital calipers,
and volume calculated (length 3 width2)/2. Pair feeding was achieved by
monitoring food intake of ‘untreated’ tumor group each 24 hr and providing
the pair-fed group with that amount of food for the following 24 hr period.
Mice received subcutaneous (s.c.) injection of PBS ± 5 3 105–5 3 106 cells1376 Cell 162, 1365–1378, September 10, 2015 ª2015 Elsevier Inc.on experiment day 1 using an insulin syringe. Antibodies were administered
by i.p. injection.
Grip-Strength Test
Whole-body strength was assessed on day 21 using a grip-strength meter (Co-
lumbus Instruments, Columbus, OH, USA) as described (Murphy et al., 2012).
Assessment of Functional Properties of TA Muscles
On day 22 (C-26 study) or day 11 (MEF study), mice were anesthetized with
sodium pentobarbitone (i.p.; Nembutal; 60 mg/kg), and the contractile proper-
ties of the mouse TA muscle assessed (Murphy et al., 2010).
Skeletal Muscle Histology
Serial sections (5 mm) cut transversely through the TA muscle using a refriger-
ated (20C) cryostat (CTI Cryostat; IEC, Needham Heights, MA, USA).
Sections were reacted with the following: laminin (Sigma-Aldrich) for mean
myofiber cross-sectional area (CSA); SDH for oxidative enzyme activity; and
N2.261 (developed by Dr Helen Blau, obtained from the Developmental
Studies Hybridoma Bank) for percentage myosin IIa isoforms (Murphy et al.,
2010). Digital images were obtained using an upright microscope (Axio Imager
D1, Carl Zeiss, Go¨ttingen, Germany), controlled and quantified by AxioVision
AC software (Carl Zeiss).
Real-Time PCR Analyses
Total RNAwas extracted from 10–20mg TAmuscle using a PureLink RNAMini
Kit (Invitrogen). RNA was transcribed into cDNA using the Invitrogen Super-
Script VILO cDNA Synthesis Kit. Real-Time PCR with primers for MuRF-1,
atrogin-1, IL-6, and TNF was performed (Murphy et al., 2010). Single-stranded
DNA (ssDNA) content in each sample was determined using Quanti-iT Oli-
Green ssDNA Assay Kit (Molecular Probes, Eugene, OR, USA). Gene expres-
sion was quantified by normalizing logarithmic cycle threshold (CT) value
(2CT) to cDNA content of each sample to obtain the expression 2CT/cDNA
content (ng.ml1).
Activin A Model of Muscle Atrophy
AAV vectors carrying activin A expression cassette, or control AAV, were in-
jected at a dose of 1 3 109 vector genomes into TA muscles of 8-week-
old male isoflurane anaesthetized C57BL/6 mice, as described (Chen et al.,
2014). Randomly assigned cohorts received a total of six antibody injections
over 4 weeks beginning 4 days after AAV vector injection. TA muscles from
both hindlimbs were excised at the experimental endpoint.
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